

Online resource 3

Supplementary Table: First pregnancy in Hodgkin lymphoma survivors, comparing pelvic radiotherapy versus no pelvic radiotherapy.

		Pelvic RT*	No pelvic RT	P value
		n=14	n=70	
Ever attempted to become pregnant ^a	n (%)	12 (85.7%)	35 (50.0%)	0.031
		n=12	n=35	
Ever pregnant	n (%)	10 (83.3%)	33 (94.3%)	0.266
Ever achieved a live birth	n (%)	8 (80.0%)	30 (90.9%)	0.575
Ever miscarried	n (%)	3 (30.0%)	7 (21.2%)	0.674
Known outcomes for (first) pregnancies within cohort		n=10	n=33	
Age at first pregnancy (years)	Median (IQR)	29.0 [19.9;32.8]	27.0 [20.8;35.6]	0.243
Currently pregnant (first pregnancy)	n(%)	0 (0.0%)	3 (9.1%)	1.000
Live birth	n (%)	7 (70.0%)	27 (81.8%)	0.413
Still birth	n (%)	0 (0%)	0 (0%)	-
Miscarriage	n (%)	1 (10.0%)	2 (6.1%)	0.558
APLA	n (%)	2 (20.0%)	1 (3.0%)	0.130
Ectopic pregnancy	n (%)	0 (0%)	0 (0%)	-
Time to pregnancy (TTP) (months)	Median (IQR)	7.0 [1.6;55.0]	3.0 [1.0;24]	0.120
	n (%) with TTP >12 months	4 (40.0%)	6 (18.8%)	0.213
Use of ART	n (%)	1 (10.0%)	1 (3.0%)	0.415
	- IUI	0 (0.0%)	1 (3.0%)	
	- IVF/ICSI	1 (10.0%)	0 (0.0%)	
Obstetric outcomes				
Birth weight (gram)	Median (IQR)	3500.0 [3003.8;4055.0]	3217.5 [1552.5;4442.5]	0.301
Small for gestational age (SGA)	n (%)	1 (14.3%)	3 (11.1%)	1.000
GA at delivery	Median (IQR)	39.0 [38.0;40.9]	40.0 [31.3;42.0]	0.694
Preterm delivery	n (%)	0 (0.0%)	3 (11.1%)	1.000

RT; radiotherapy

*Median received pelvic radiation dose was 26 Gy (20-40)

Differences were analyzed using chi-square test or Fisher's exact tests for categorical variables and Mann-Whitney U-test for continuous variables (because of non-normal distribution).

Article title: Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma

Journal: Journal of Cancer Research and Clinical Oncology

Authors: K.C.E. Drechsel*, S.L. Broer, F. Stoutjesdijk, J.W.R. Twisk, M.H. van den Berg, C.B. Lambalk, F.E. van Leeuwen, A. Overbeek, M.M. van den Heuvel-Eibrink, W. van Dorp, A.C.H. de Vries, J.J. Loonen, H.J. van der Pal, L.C. Kremer, W.J. Tissing, B. Versluys, G.J.L. Kaspers, E. van Dulmen-den Broeder**, M.A. Veening**
on behalf of the LATER-VEVO study group.

**shared last authorship

***Corresponding author:**

Drs. K.C.E. Drechsel, MD

Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Princess Máxima Centre for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Cancer Center Amsterdam, Amsterdam UMC, location VUmc, VU Amsterdam, 1007 MB Amsterdam, Netherlands.

k.c.e.drechsel@amsterdamumc.nl / ORCHID iD: 0000-0001-9879-4678